Menin-MLL inhibitor MI-2|1271738-62-5|-陌孚医药/Medlife

您当前的位置：

Menin-MLL inhibitor MI-2

目录号: PL13449 纯度: ≥99%

Menin-MLL inhibitor MI-2 抑制 Menin-MLL 相互作用，IC50 为 446±28 nM。

CAS No. :1271738-62-5

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Menin-MLL inhibitor MI-2
中文别名	4-[4-(4,5-二氢-5,5-二甲基-2-噻唑基)-1-哌嗪基]-6-丙基噻吩并[2,3-D]嘧啶;MI-2 抑制剂
英文名称	Menin-MLL inhibitor MI-2
英文别名	4-(4-(5,5-Dimethyl-4,5-dihydrothiazol-2-yl)piperazin-1-yl)-6-propylthieno[2,3-d]pyrimidine;MI-2;4-(4-(5,5-Dimethyl-4,5-dihydrothiazol-2-yl)-piperazin-1-yl)-6-propylthieno[2,3-d]pyrimidine;MI-?2;MI-2 (Menin-MLL Inhibitor);AK118880;CS-0771;HY-15222;Menin-MLL inhibitor 2;QCR-218;Thieno[2,3-d]pyrimidine, 4-[4-(4,5-dihydro-5,5-dimethyl-2-thiazolyl)-1-piperazinyl]-6-propyl-;4-[4-(5,5-dimethyl-4H-1,3-thiazol-2-yl)piperazin-1-yl]-6-propylthieno[2,3-d]pyrimidine;4-[4-(5,5-Dimethyl-4,5-Dihydro-1,3-Thiazol-2-Yl)piperazin-1-Yl]-6-Propylthieno[2,3-D]pyrimidine;mi-2-menin-mll-inhibitor;MI 2 (Menin-MLL Inhibitor);MI-2, Menin-MLL inhibitor 2;AOB1818;Menin-MLL inhibitor MI-2
Cas No.	1271738-62-5
分子式	C₁₈H₂₅N₅S₂
分子量	375.55
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	Menin-MLL inhibitor MI-2 抑制 Menin-MLL 相互作用，IC₅₀ 为 446±28 nM。
生物活性	Menin-MLL inhibitor MI-2 is a Menin-MLL interaction inhibitor with IC 50 of 446±28 nM.
性状	Solid
IC50 & Target[1][2]	IC50: 446±28 nM (Menin-MLL)
体外研究(In Vitro)	Menin-MLL inhibitor MI-2 very effectively blocks proliferation of MLL-AF9 and MLL-ENL transduced BMC, with GI50 values of about 5 μM. Assessment of diverse hydrophobic groups at R1 led to the development of several compounds with IC50 values in the nanomolar range, including MI-2 (IC50= 446±28 nM) and MI-3 (IC50=648±25 nM).The dissociation constants measured for the menin-MLL inhibitors are at the nanomolar level, Kd=158 nM for MI-2. MI-2 can access the protein target and very effectively inhibit the menin-MLL-AF9 interaction in human cells. Furthermore, MI-2 shows only a small effect on the cell growth of E2A-HLF transduced BMC (GI50>50 μM), which may be due to inhibition of the menin interaction with wild-type MLL. Treatment with MI-2 results in GI50 values below 10 μM in MV4;11 (harboring MLL-AF
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Grembecka J, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nature Chemical Biology (2012), 8(3), 277-284.

溶解度数据	In Vitro: DMSO : 50 mg/mL (133.14 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品